CYP24A1 is an independent prognostic marker of survival in patients with lung adenocarcinoma

Clinical Cancer Research

Volumn 17, Issue 4, 2011, Pages 817-826

  Chen, Guoan ^a   Kim, So Hee ^a,c   King, Amanda N ^a,c   Zhao, Lili ^b   Simpson, Robert U ^a   Christensen, Paul J ^a,c   Wang, Zhuwen ^a   Thomas, Dafydd G ^a   Giordano, Thomas J ^a   Lin, Lin ^a   Brenner, Dean E ^a,c   Beer, David G ^a   Ramnath, Nithya ^a,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1ALPHA, 25 DIHYDROXYVITAMIN D3; CYTOCHROME P450; CYTOCHROME P450 24A1; MESSENGER RNA; UNCLASSIFIED DRUG; VITAMIN D;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; FOLLOW UP; GENE AMPLIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; CALCITRIOL; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOSTATIC AGENTS; GENETIC ASSOCIATION STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; RECEPTORS, CALCITRIOL; RNA, MESSENGER; STEROID HYDROXYLASES; UP-REGULATION;

EID: 79951837361     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1789     Document Type: Article

References (38)

1. Jemal A, Thun MJ, Ries LA, Howe HL, Weir HK, Center MM, et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 2008;100:1672-94.
2. Moan J, Porojnicu AC, Dahlback A, Setlow RB. Addressing the health benefits and risks, involving vitamin D or skin cancer, of increased sun exposure. Proc Natl Acad Sci USA 2008;105:668-73. (Pubitemid 351171766)
3. Bostick RM, Potter JD, Sellers TA, McKenzie DR, Kushi LH, Folsom AR. Relation of calcium, vitamin D, and dairy food intake to incidence of colon cancer among older women. The Iowa Women's Health Study. Am J Epidemiol 1993;137:1302-17. (Pubitemid 23215031)
4. Mohr SB, Garland CF, Gorham ED, Grant WB, Garland FC. Relationship between low ultraviolet B irradiance and higher breast cancer risk in 107 countries. Breast J 2008;14:255-60.
5. Braun MM, Helzlsouer KJ, Hollis BW, Comstock GW. Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States). Cancer Causes Control 1995;6:235-9.
6. Kilkkinen A, Knekt P, Heliovaara M, Rissanen H, Marniemi J, Hakulinen T, et al. Vitamin D status and the risk of lung cancer: a cohort study in Finland. Cancer Epidemiol Biomarkers Prev 2008; 17:3274-8.
7. Zhou W, Heist RS, Liu G, Asomaning K, Neuberg DS, Hollis BW, et al. Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients. J Clin Oncol 2007;25:479-85. (Pubitemid 350002952)
8. Koshizuka K, Koike M, Asou H, Cho SK, Stephen T, Rude RK, et al. Combined effect of vitamin D3 analogs and paclitaxel on the growth of MCF-7 breast cancer cells in vivo. Breast Cancer Res Treat 1999; 53:113-20. (Pubitemid 29161117)
9. Hershberger PA, Modzelewski RA, Shurin ZR, Rueger RM, Trump DL, Johnson CS. 1,25-Dihydroxycholecalciferol (1,25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21 (Waf1/Cip1) in vitro and in vivo. Cancer Res 1999;59:2644-9.
10. McElwain MC, Modzelewski RA, Yu WD, Russell DM, Johnson CS. Vitamin D: an antiproliferative agent with potential for therapy of squamous cell carcinoma. Am J Otolaryngol 1997;18:293-8. (Pubitemid 27358009)
11. Liu M, Lee MH, Cohen M, Bommakanti M, Freedman LP. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 1996;10:142-53. (Pubitemid 26049905)
12. Yee SW, Campbell MJ, Simons C. Inhibition of Vitamin D3 metabolism enhances VDR signalling in androgen-independent prostate cancer cells. J Steroid Biochem Mol Biol 2006;98:228-35. (Pubitemid 43344252)
13. Bernardi RJ, Trump DL, Yu WD, McGuire TF, Hershberger PA, Johnson CS. Combination of 1alpha,25-dihydroxyvitamin D(3) with dexamethasone enhances cell cycle arrest and apoptosis: role of nuclear receptor cross-talk and Erk/Akt signaling. Clin Cancer Res 2001;7:4164-73.
14. McGuire TF, Trump DL, Johnson CS. Vitamin D(3)-induced apoptosis of murine squamous cell carcinoma cells. Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1. J Biol Chem 2001;276:26365-73.
15. Chung I, Karpf AR, Muindi JR, Conroy JM, Nowak NJ, Johnson CS, et al. Epigenetic silencing of CYP24 in tumor-derived endothelial cells contributes to selective growth inhibition by calcitriol. J Biol Chem 2007;282:8704-14. (Pubitemid 47093535)
16. Nakagawa K, Kawaura A, Kato S, Takeda E, Okano T. 1 alpha,25- Dihydroxyvitamin D(3) is a preventive factor in the metastasis of lung cancer. Carcinogenesis 2005;26:429-40.
17. Nakagawa K, Sasaki Y, Kato S, Kubodera N, Okano T. 22-Oxa-1alpha,25- dihydroxyvitamin D3 inhibits metastasis and angiogenesis in lung cancer. Carcinogenesis 2005;26:1044-54. (Pubitemid 41214297)
18. Light BW, Yu WD, McElwain MC, Russell DM, Trump DL, Johnson CS. Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. Cancer Res 1997;57:3759-64. (Pubitemid 27381220)
19. Moffatt KA, Johannes WU, Miller GJ. 1Alpha,25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines. Clin Cancer Res 1999;5:695-703. (Pubitemid 29131982)
20. Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 2007;7:684-700. (Pubitemid 47327412)
21. Masuda S, Byford V, Arabian A, Kaufmann M, Jones G. Altered pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 in the blood and tissues of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) null mouse. Endocrinology 2005;146:825-34. (Pubitemid 40129840)
22. Hansdottir S, Monick MM, Hinde SL, Lovan N, Look DC, Hunninghake GW. Respiratory epithelial cells convert inactive vitamin D to its active form: potential effects on host defense. J Immunol 2008; 181:7090-9.
23. Anderson MG, Nakane M, Ruan X, Kroeger PE, Wu-Wong JR. Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemother Pharmacol 2006;57:234-40. (Pubitemid 41779843)
24. Mimori K, Tanaka Y, Yoshinaga K, Masuda T, Yamashita K, Okamoto M, et al. Clinical significance of the overexpression of the candidate oncogene CYP24 in esophageal cancer. Ann Oncol 2004;15:236-41. (Pubitemid 38262621)
25. BeerDG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002;8:816-24.
26. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7. (Pubitemid 28331029)
27. Raponi M, Dossey L, Jatkoe T, Chen G, Lee G, Taylor JM, et al. MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res 2009;69: 5776-83.
28. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004;6:1-6. (Pubitemid 38391943)
29. Kim B, Lee HJ, Choi HY, Shin Y, Nam S, Seo G, et al. Clinical validity of the lung cancer biomarkers identified by bioinformatics analysis of public expression data. Cancer Res 2007;67:7431-8. (Pubitemid 47206573)
30. Parise RA, Egorin MJ, Kanterewicz B, Taimi M, Petkovich M, Lewet AM, et al. CYP24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancer. Int J Cancer 2006; 119:1819-28. (Pubitemid 44356838)
31. van Dekken H, Vissers K, Tilanus HW, Kuo WL, Tanke HJ, Rosenberg C, et al. Genomic array and expression analysis of frequent high-level amplifications in adenocarcinomas of the gastro-esophageal junction. Cancer Genet Cytogenet 2006;166:157-62.
32. Yamamoto S, Midorikawa Y, Morikawa T, Nishimura Y, Sakamoto H, Ishikawaet S, et al. Identification of chromosomal aberrations of metastatic potential in colorectal carcinoma. Genes Chromosomes Cancer 2010;49:487-96.
33. Albertson DG, Ylstra B, Segraves R, Collins RC, Dairkee SH, Kowbelet D, et al. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet 2000;25:144-6. (Pubitemid 30394982)
34. Zitzelsberger H, Engert D, Walch A, Kulka U, Aubele M, Hofleret H, et al. Chromosomal changes during development and progression of prostate adenocarcinomas. Br J Cancer 2001;84:202-8. (Pubitemid 32113447)
35. Lin R, Nagai Y, Sladek R, Bastien Y, Ho J, Petrecca K, et al. Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. Mol Endocrinol 2002;16:1243-56. (Pubitemid 34621073)
36. Komagata S, Nakajima M, Takagi S, Mohri T, Taniya T, Yokoi T. Human CYP24 catalyzing the inactivation of calcitriol is post-transcriptionally regulated by miR-125b. Mol Pharmacol 2009;76:702-9.
37. Zhu J, Barycki R, Chiellini G, Deluca HF. Screening of selective inhibitors of 1alpha,25-dihydroxyvitamin D3 24-hydroxylase using recombinant human enzyme expressed in Escherichia coli. Biochemistry 2010;49:10403-11.
38. Aboraia AS, Makowski B, Bahja A, Prosser D, Brancale A, Jones G, et al. Synthesis and CYP24A1 inhibitory activity of (E)-2-(2-substituted benzylidene)- and 2-(2-substituted benzyl)-6-methoxy-tetralones. Eur J Med Chem 2010;45:4427-34.